source
- REVELUTION-2 Trial Is Evaluating Cardiovascular Risk With Relugolix Plus Abiraterone Acetate in High-Risk Prostate CancerSagar A. Patel, MD, discusses the REVELUTION-2 trial evaluating cardiovascular safety with hormone therapy in prostate cancer.onclive · 2mo ago↗ source
- AstraZeneca follows Merck with Phase 3 win in bladder cancerA combination of AstraZeneca's Imfinzi with Pfizer and Astellas’ Padcev kept more bladder cancer patients alive than standard of care, the company said Thursday. AstraZeneca said it would seek appr…Endpoints · 2mo ago↗ source
- STAT+: BeOne wins FDA approval in lymphoma raceDiamantas takes the reins, Regenxbio stakes claim in Duchenne gene therapy, and more biotech news from The Readout